Director, US Tx Strategic Pricing

Company Description

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on X, Facebook, Instagram, YouTube, LinkedIn and Tik Tok.

Job Description

Primary Job Function

The Director, US Tx Strategic Pricing, will be responsible for calculating and articulating the financial impact of complex US pricing topics across the US Therapeutics business. This includes high-priority areas such as the Inflation Reduction Act and International Reference Pricing Impact. The role demands agility in responding to evolving market dynamics and healthcare policy changes.

The US healthcare landscape is undergoing unprecedented transformation, driven by regulatory shifts from governing bodies such as the FDA and CDC, as well as new government initiatives aimed at optimizing pharmaceutical costs for American patients. These changes are compelling pharmaceutical organizations to adapt their business practices and financial strategies, with significant implications not only in the US but also globally. In this environment, this position plays a critical role in clearly explaining the financial impact of complex issues to senior management, including the C-Suite.

In addition, the Director, US Tx Strategic Pricing, will be responsible for leading a high performing analytics team to support the dynamic needs of the various business stakeholders and initiatives that require pricing expertise.

This position reports to the Director, US Pricing / IRA.

Core Job Responsibilities:

IRA / Strategic Pricing

• Lead financial analytics and presentations associated with the impact of the Inflation Reduction Act across the entire US Therapeutics portfolio. This portfolio is comprised of ~ 15 key products with varying reimbursement types (Part B, Part D, 340B, Medicaid, Commercial) and access issues across